China-based Novogene to set up genome sequencing centre at Babraham Research Campus
Company has largest sequencing capacity in the world
Novogene is to establish its first European genomic sequencing centre at Babraham Research Campus.
The China-based global provider of genomic services and solutions said it was seeking to meet the growing demand from European customers.
Dr Ruiqiang Li, founder and CEO of Novogene, said: “We are proud to set up our first European Laboratory at the Babraham Research Campus.
“Our UK lab is our first step towards addressing the increasing demand for our European customers, and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”
The Novogene UK Genomic Sequencing Center will feature a full automation system and the latest illumina NovaSeq and super computing platforms.
The new facility will enable Novogene to provide next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies and biotechnology companies.
Derek Jones, CEO Babraham Bioscience Technologies, which manages and develops the campus said: “I am extremely pleased to welcome Novogene to the Babraham Research Campus.
“The role of genomics is rapidly evolving and the Cambridge cluster has become a hub for innovation in this area, attracting leading organisations, like Novogene, to locate here.
“Close proximity to academic and commercial collaborators - both on campus and within the wider cluster - is hugely beneficial to the organisations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”
Novogene, established in 2011, has its headquarters in Beijing and branches in Hong Kong, and the US, along with genomic sequencing labs at the University of California, China and Singapore. It has the largest sequencing capacity in the world and has completed nearly 20,000 projects and sequenced 370,000 samples for more than 10,000 global customers.
Its arrival represents further good news for Babraham, which announced last week that PredictImmune had set up its HQ there.
Read more
Peter Pack tells of ‘milestone’ as Crescendo Biologics raises £51m for novel cancer therapy
Enter the 2018 Cambridge Independent Science and Technology Awards
Direct-to-consumer genetic tests: what’s in it for you?
